Monofilament conversion of PURASORB PLC 7015 B on a single-screw extruder with L/D 24:1 uses a feed-zone temperature of 150°C, a compression-zone temperature of 165°C, a metering-zone temperature of 180°C, and a die temperature of 175°C. The pellets are pre-dried under vacuum at 120°C for 8 h to reduce moisture below 100 ppm, determined by coulometric Karl Fischer titration per ISO 15512:2019. The melt is filtered through a 40 µm screen pack to remove gel particles and black specks. Extruded monofilament is quenched in water at 20°C, then drawn at a ratio of 4:1 to 6:1 in a 55°C water bath. Draw ratios below 3:1 produce oriented fibers with tensile strength below 300 MPa, while draw ratios above 6:1 initiate surface fibrillation because the caprolactone-rich amorphous domains separate under high orientation. Annealing at 70°C for 12 h under nitrogen reduces free shrinkage to 2–3% when measured after 24 h in water at 37°C. Tensile and knot-pull testing follows ASTM D2256-21 for monofilament yarns; suture diameter and knot-pull acceptance limits are defined by the compendial monograph for synthetic absorbable sutures. Gamma sterilization at 25 kGy lowers inherent viscosity, and molecular weight retention below 85% of the pre-sterilization value is treated as a batch rejection criterion.

What Residual ε-Caprolactone Level Is Acceptable in Emulsion-Derived Depot Microspheres?

Solvent evaporation microencapsulation of PURASORB PLC 7015 B with a peptide or small molecule API uses dichloromethane as the dispersed phase and aqueous polyvinyl alcohol as the continuous phase. The copolymer is dissolved at 15% w/v in dichloromethane and emulsified with a rotor-stator at 10,000 rpm for 2 min. Solvent removal under stirring at 500 rpm and 25°C for 4 h produces microspheres with a volume mean diameter of 20–70 µm when measured by laser diffraction per ISO 13320:2020. Residual dichloromethane is limited to 600 ppm under ICH Q3C Option 1, determined by headspace gas chromatography per USP 467. Residual ε-caprolactone monomer is more problematic in depot forms because caprolactone migrates to the particle surface and can increase initial burst release; a ceiling of 0.5 wt% monomer by GC-FID is therefore applied in process validation. In vitro release in phosphate-buffered saline at 37°C and pH 7.4 is monitored by HPLC per USP 621 over 28 d. Release follows a biphasic profile with an initial diffusion phase governed by surface-associated drug and a second hydrolysis-controlled phase. Microsphere morphology is checked by scanning electron microscopy after lyophilization; surface pores larger than 10 µm correlate with burst release above 20% of payload. Published data for this specific PURASORB grade in microsphere form is limited; process development relies on in-house data and comparison with analogous lactide-caprolactone copolymers.

Cast film fabrication for absorbable adhesion barrier stock uses a 10 wt% solution of the copolymer in chloroform, spread onto a PTFE-coated glass plate with a knife gap set to 500 µm. Solvent is removed at 25°C for 12 h, then under vacuum at 40°C for 24 h to reduce residual chloroform below 60 ppm per USP 467. The dry film is 50–200 µm thick. Because the caprolactone component lowers glass transition below ambient temperature, the film remains compliant and can be folded without fracture at 25°C. Tensile properties are measured by ISO 527-3:2018 with a test speed of 10 mm/min; elongation at break above 200% is typical for solvent-cast films. Suture pullout resistance is assessed with a 3-0 braided suture passed through the film 2 mm from the edge; failure load above 1.5 N is required in internal handling specifications. In vitro degradation is evaluated in phosphate-buffered saline at 37°C according to ASTM F1635-16, with mass loss recorded at 4, 13, 26, and 52 weeks. The degradation profile is suitable for a temporary barrier that maintains mechanical integrity for at least 8 weeks after implantation, then loses mass over 12–24 months. Cytotoxicity and implantation evaluations are conducted per ISO 10993-5:2009 and ISO 10993-6:2016.

When β-TCP Loading Reaches 30 wt% in Compression-Molded Interference Screws

Melt compounding of the copolymer with β-tricalcium phosphate is performed in a 25 mm twin-screw extruder with L/D 40:1, using a screw profile that includes two kneading blocks and a low-shear discharge zone. Dried polymer is fed at 5 kg/h with the barrel profile set from 150°C to 180°C. Addition of β-TCP at 15 wt% raises melt viscosity by approximately 25% relative to unfilled polymer at 180°C and 100 s⁻¹ in a capillary rheometer per ISO 11443:2021; at 30 wt% the viscosity increase is 60–80%, and fill pressures during subsequent compression molding rise accordingly. Above 30 wt% β-TCP, screw torque approaches the extruder’s upper limit and filler agglomeration creates surface defects on molded parts. The compounded strand is pelletized after air cooling and then compression molded at 170°C and 100 bar for 3 min. Molded screws are tested for flexural strength by ASTM D790-17 and implantation properties by ASTM F2502-17. The β-TCP phase buffers acidic hydrolytic degradation products, helping to maintain local pH above 6.5 in in vitro degradation medium at 37°C. The screws must be packaged in nitrogen-flushed foil pouches because moisture absorption above 0.3 wt% before molding generates voids at the polymer–filler interface.

Injection molding of absorbable vascular clips on a 35 mm reciprocating screw machine with L/D 20:1 uses a clamped mold with a core temperature of 50°C to prevent sticking and gate blush. Pellets are dried under vacuum at 120°C for 6 h. The barrel profile is 150°C to 180°C, injection pressure is 800 bar, and hold pressure is 600 bar for 4 s. A cold runner with a tunnel gate 1.0 mm in diameter is used; the gate freezes at 3–5 s, after which the part is ejected. Because the copolymer has a glass transition below 25°C, the molded clips require no annealing and retain a ductile failure mode when tested at 37°C. Tensile strength and elongation are measured according to ASTM D638-14 on Type V specimens. Residual stress is evaluated by polarized light microscopy; unacceptable stress birefringence near the gate is controlled by increasing mold temperature from 25°C to 50°C. Sterilization by ethylene oxide at 37°C and 400 mg/L EO with a relative humidity of 60% is used where gamma-induced chain scission would reduce clip open retention force. The clip’s bioburden and sterility assurance level follow ISO 11135:2014 and ISO 11137-2:2013.

Solvent-Cast Conduit Wall Anisotropy and Suture Pullout Resistance

A 5% w/v solution of the copolymer in dichloromethane is applied by dip-coating onto a rotating braided poly(L-lactide-co-ε-caprolactone) tube with an outer diameter of 4 mm. Each dip is followed by drying at 25°C for 30 min; after 6 dips, the wall thickness reaches 180–250 µm. The final conduit is dried under vacuum at 40°C for 24 h and residual dichloromethane is tested by headspace GC per USP 467 with a limit of 600 ppm. The laminated wall exhibits anisotropic tensile behavior because the underlying braid contributes longitudinal stiffness while the cast copolymer provides hoop compliance. Suture pullout resistance is measured by passing a 7-0 monofilament suture through the wall 1 mm from the cut edge and pulling at 10 mm/min; a failure load of 0.8–1.5 N is typical. Kink resistance is evaluated by bending the conduit around mandrels with radii from 5 mm to 10 mm; luminal occlusion is measured by a calibrated tapered probe. In vitro degradation is run in phosphate-buffered saline at 37°C for 52 weeks per ASTM F1635-16, and the lattice retains burst strength above 50% of initial through 24 weeks. Published data for this specific solvent-cast conduit construction is limited; the values cited are design targets used in benchtop evaluations, not completed clinical performance data.

Gamma radiation at 25 kGy changes inherent viscosity, not crystallinity

Sterilization validation for a lactide-caprolactone device is performed under ISO 11137-2:2013 using the VDmax25 dose-substantiation method when bioburden is below 100 CFU/device. At a sterilizing dose of 25 kGy, the copolymer undergoes chain scission that is observable as a reduction in inherent viscosity of 10–25% when measured in chloroform at 25°C and 0.1 g/dL by ISO 1628-3:2018. The effect is dose-rate dependent; a slower dose rate above 2 kGy/h reduces free-radical recombination time and can produce a smaller viscosity loss than a fast cycle above 10 kGy/h. Crystallinity does not increase substantially in the lactide-rich amorphous domains after irradiation, as shown by differential scanning calorimetry at 10 K/min under nitrogen. The post-irradiation glass transition remains below body temperature, so the sterilized device retains flexibility. Oxidation during storage is limited by packaging in a nitrogen-filled foil pouch with oxygen below 0.5%; headspace oxygen is monitored by gas chromatography. The manufacturer’s specifications for post-sterilization molecular weight retention should be established on each lot because published data for this exact formulation under all irradiation dose rates is limited. A compliance matrix for finished device submission is summarized below.